May 24, 2012

CLOSE

To subscribe to updates from this journal click Confirm. Updates will be displayed in your default RSS reader.

Produced and published by Remedica Medical Education and Publishing Limited.

» Contact us

International Journal of Advances in Rheumatology

» Advanced search

Paper of the Month - April, 2011

Please login to access this article in full. Click here to register for free now!

Registered users login here:

Email Address:
Password:

If you have forgotten your password click here


0 rating

The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept

Jamnitski A, Bartelds GM, Nurmohamed MT et al.

Jamnitski A, Bartelds GM, Nurmohamed MT et al.
Ann Rheum Dis2011;70:284–8.

This group had previously found that switching antitumor necrosis factor agents in rheumatoid arthritis was more useful when failure of the initial agent was associated with the presence of anti-drug antibodies. Here, they studied patients starting etanercept and reach the same conclusion, suggesting that anti-drug antibody testing may help identify patients who should be switched to another class of drug.

Please login or register to continue reading this article

View Archive »


Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials - March, 2012
Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a Phase II, randomized, placebo-controlled, dose-finding trial - February, 2012
Association between disease modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis - January, 2012
Bone edema on magnetic resonance imaging is an independent predictor of rheumatoid arthritis development in patients with early undifferentiated arthritis - December, 2011
Acquisition of the rheumatoid arthritis HLA shared epitope through microchimerism - November, 2011
The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases - October, 2011
MRI in early rheumatoid arthritis: synovitis and bone marrow oedema are independent predictors of subsequent radiographic progression - September, 2011
Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle–Wells syndrome - August, 2011
The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study - July, 2011
Rheumatoid arthritis-interstitial lung disease-associated mortality - June, 2011
Impact of obesity and knee osteoarthritis on morbidity and mortality in older Americans - May, 2011
The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept - April, 2011
Beneficial effect of 1-year etanercept treatment on the lipid profile in responding patients with rheumatoid arthritis: the ETRA study - March, 2011
Musculoskeletal pain is associated with very low levels of vitamin D in men: results from the European Male Ageing Study - February, 2011
Individual susceptibility to periprosthetic osteolysis is associated with altered patterns of innate immune gene expression in response to pro-inflammatory stimuli - January, 2011
Rheumatologists’ awareness of and screening practices for hepatitis B virus infection prior to initiating immunomodulatory therapy - December, 2010
Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis - November, 2010
Inflammatory markers in patients with coronary artery disease with and without inflammatory rheumatic disease - October, 2010
Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk? - September, 2010
Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register - August, 2010
The role of dynamic contrastenhanced MRI in the differential diagnosis of psoriatic and rheumatoid arthritis - July, 2010
Postpartum onset of rheumatoid arthritis and other chronic arthritides: results from a patient register linked to a medical birth registry - June, 2010
Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study) - May, 2010
Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial - April, 2010
Involvement of MAPKs and NFkappaB in tumor necrosis factor alpha-induced vascular cell adhesion molecule 1 expression in human rheumatoid arthritis synovial fibroblasts - March, 2010
DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis - February, 2010
The time has come to limit the placebo period in rheumatoid arthritis trials to 3 months: a systematic comparison of 3- and 6-month response rates in trials of biological agents - January, 2010
The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial - 2009
Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON ): a multicentre, double-blind, double-dummy, randomised controlled trial - 2009
Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis - 2009

READER POLL

How have the “Treat-to-Target” recommendations affected your day-to-day practice?

Altered the types of patient assessments conducted in the clinic
Altered the frequency of patient assessments
Altered the types and frequencies of patient assessments conducted
Has not changed practice, but anticipate that it may do so in the next 1–3 years
Do not expect it to change practice at all

WEB LINKS

http://ard.bmj.com/conten
/70/2/284.long

Find us on
Facebook

Post Page On

SUBMIT AN ARTICLE

» Click here

© Remedica 2012. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without the prior permission of the copyright owners. While every effort is made by the publishers and editorial board to see that no inaccurate or misleading data, opinions, or statements appear in this journal, they wish to make it clear that the material contained in the publication represents a summary of the independent evaluations and opinions of the authors and contributors. As a consequence, the board, publishers, and any supporting company accept no responsibility for the consequences of any such inaccurate or misleading data or statements. Neither do they endorse the content of the publication or the use of any drug or device in a way that lies outside its current licensed application in any territory. For detailed information on any drugs or devices discussed in this publication, readers are advised to consult the manufacturer’s prescribing information.

Produced and published by Remedica Medical Education and Publishing Limited.

May 24, 2012 CLOSE To subscribe to updates from this journal click Confirm. Updates will be displayed in your default RSS reader. Produced and published by Remedica Medical Education and Publishing Limited. » Contact us

International Journal of Advances in Rheumatology » Advanced search